Roivant Sciences

ROIV • NASDAQ • Stock Fundamentals

Roivant is a biopharmaceutical company that utilizes a decentralized 'Vant' model to accelerate the development and commercialization of transformative medicines. The company advances a diverse pipeline of small molecules and biologics across immunology, inflammation, and pulmonary hypertension by creating nimble, subsidiary-focused business units. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups to complement its core drug development engine.

Market Cap$20.4B

Revenue TTM$8.3M

Free Cash Flow TTM-$758.6M

Employees908.0

CEOMatthew Gline

CountryUnited Kingdom

Healthcare

Biotechnology

SegmentsBiotechnology, Pharmaceuticals, Health Technology

Business ModelsResearch and Development, Licensing and Royalties, Venture Studio

Most Recent EarningsFeb 6, 2026 · 3 months agoQ4 2025 · FQ3 FY2026

View report

Next EarningsJul 1, 2026 · in a monthBefore Market Open · Q2 2025 · FQ1 FY2026

Income Statement Balance Sheet Cash Flow Segments

Financials

Based on Q4 2025 · FQ3 FY2026 filing

View all metrics

D/E2.37%

Current Ratio18.37

Total Debt$107.4M

Cash$1.4B

CapEx TTM$14.0M

Business Segments

View segment metrics

Biopharmaceutical Pipeline

primary

The primary business focused on the clinical development and commercialization of drug candidates through specialized subsidiary companies known as Vants.

Products

Brepocitinib, IMVT-1402, Batoclimab, Mosliciguat

Customers

Patients, Healthcare Providers, Pharmacy Benefit Managers

Technology & Discovery Platforms

moderate

Incubation of health technology startups and discovery-stage entities that provide computational and logistical support for drug development and data management.

Products

LNP Technology, VantAI, Lokavant, Datavant

Customers

Biopharmaceutical Companies, Clinical Research Organizations, Healthcare Data Analytics Firms

Segment Financials

Brepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

View metric

Mosliciguat — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

View metric

Anti-FcRn franchise—contractual costs related to batoclimab program discontinuation — Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)

View metric

Other development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

View metric

Reportable Segment — Acquired in-process research and development

View metric

Business Overview

Competitive Position

Roivant maintains a unique position through its decentralized Vant model, which combines the focus of a biotech startup with the scale and resources of a large pharmaceutical firm.

Geographies

United States, European Union, United Kingdom, Japan

Customer Segments

Healthcare Providers, Pharmaceutical Companies, Government Health Programs

Upstream Dependencies

Academic Research Institutions, Contract Manufacturing Organizations, Contract Research Organizations, Pharmaceutical Licensors

Downstream Customers

Wholesale Distributors, Specialty Pharmacies, Hospitals, Government Payors

Competitors & Partners

Competitors

Amgen

AMGN

Competitor in immunology and inflammatory disease treatments

Moderna

MRNA

Litigation adversary regarding LNP delivery technology

Similar Companies

Royalty Pharma

RPRX

ALN

Alnylam Pharmaceuticals

ALNY

Viatris

VTRS

Bristol-Myers Squibb

BMY

Biogen

BIIB

AbbVie

ABBV

Pfizer

PFE

Merck & Co.

MRK

Gilead Sciences

GILD

Johnson & Johnson

JNJ

Eli Lilly

LLY

IQVIA

IQV

Agilent Technologies

Vertex Pharmaceuticals

VRTX

ROP

Roper Technologies, Inc.

ROP

Cognizant

CTSH

Palantir Technologies Inc.

PLTR

Partners

Pfizer

PFE

Licensing partner for brepocitinib and ropsacitinib

HanAll Biopharma

Licensing partner for batoclimab and IMVT-1402

Samsung Biologics

Manufacturing and supply partner for batoclimab

Organon

OGN

Acquirer of Dermavant subsidiary

Sumitomo Pharma

Strategic alliance partner and acquirer of multiple Vants

Subsidiaries

Immunovant, Inc.

IMVT

Focused on autoimmune diseases

Priovant Therapeutics

Focused on autoimmune and inflammatory diseases

Pulmovant

Focused on pulmonary hypertension

Genevant Sciences

Focused on lipid nanoparticle (LNP) delivery technology

VantAI

Computational drug discovery platform

Lokavant

Clinical trial monitoring and data platform